This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

47/100

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Risk genes beyond APOE

Topic: Risk, prevention and care in population studies

As of a data cutoff of December 3, 2024, 243 participants were screened and 197 randomized in DIAN-TU-001 Tau NexGen trial (Cohort 1: 97; Cohort 2: 100). Baseline characteristics of Cohort 1 and Cohort 2 were similar except for cognitive values, all of which varied as expected per the differing CDR study entry criteria for the two cohorts. Mean age (standard deviation [SD]) was 47.8 (8.6) and 43.4 (8.4) years in Cohort 1 and 2, respectively. At baseline, mean CDR-SB values (SD) were 3.7 (2.1) for Cohort 1 and 0.1 (0.3) for Cohort 2. APOE4 carrier frequency is consistent with that of the general population, with 25.8% and 21.0% carriers in Cohorts 1 and 2, respectively. The most common gene type in each group was PSEN1 (Cohort 1:78.4%; Cohort 2:85.0%). The baseline characteristics for DIAN-TU-001 Tau NexGen trial were consistent with clinical features of asymptomatic and symptomatic DIAD. These characteristics were also generally consistent between Cohort 1 and Cohort 2 with the exception of clinical, and cognitive scores.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Llibre‐Guerra, J. J., Zhou, J., Schneider, L. S. S., Andreozzi, E. M., Clifford, D. B., Banerjee, S., et al. (2025). Baseline Participant Characteristics in the DIAN‐TU‐001 Trial. Alzheimer s & Dementia. https://doi.org/10.1002/alz70859_105299

Vancouver

Llibre‐Guerra JJ, Zhou J, Schneider LSS, Andreozzi EM, Clifford DB, Banerjee S, et al. Baseline Participant Characteristics in the DIAN‐TU‐001 Trial. Alzheimer s & Dementia. 2025. doi:10.1002/alz70859_105299. PMID: 41450326.

BibTeX

@article{llibreguerra2025-41450326,
  author  = {Llibre‐Guerra, Jorge J. and Zhou, Jin and Schneider, Lon S. S. and Andreozzi, Erica M. and Clifford, David B. and Banerjee, Sibabrata and Wang, Guoqiao and McDade, Eric and others},
  title   = {{Baseline Participant Characteristics in the DIAN‐TU‐001 Trial}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70859_105299},
  pmid    = {41450326},
  url     = {https://doi.org/10.1002/alz70859_105299}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

As of a data cutoff of December 3, 2024, 243 participants were screened and 197 randomized in DIAN-TU-001 Tau NexGen trial (Cohort 1: 97; Cohort 2: 100).
Baseline characteristics of Cohort 1 and Cohort 2 were similar except for cognitive values, all of which varied as expected per the differing CDR study entry criteria for the two cohorts.
Mean age (standard deviation [SD]) was 47.8 (8.6) and 43.4 (8.4) years in Cohort 1 and 2, respectively.
At baseline, mean CDR-SB values (SD) were 3.7 (2.1) for Cohort 1 and 0.1 (0.3) for Cohort 2.
APOE4 carrier frequency is consistent with that of the general population, with 25.8% and 21.0% carriers in Cohorts 1 and 2, respectively.

Why it matters

This reports baseline characteristics of participants in the DIAN-TU-001 Tau NexGen trial, which is a trial in people with dominantly inherited Alzheimer's disease. It provides no results on whether any treatment works to treat, cure or prevent Alzheimer's disease.

New to this subject? Start with our plain-English guide: Genetics →

Study details

Participants243
Effect size25.8%; 21.0%; 78.4%
Evidence strengthHigh

How this study scored 47/100

Published in a peer-reviewed journal. Scored zero for study design and randomised / blinded because the record does not state it.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record	2 / 4	Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	5 / 5	Rated “high” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	2 / 4	243 participants
Effect reported	2 / 3	Effect reported as a number, without an interval or test
Studied in people	3 / 3	Studied in people (participant count stated)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	0 / 7	Cited 0 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.0 citations a year over 3 year(s) since 2025
Impact for its field and year	0 / 6	Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	4 / 4	Last-listed author Randall John Bateman: h-index 101 (OpenAlex, whole career)
Institution's track record	2 / 3	Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multi-centre collaboration	2 / 3	OpenAlex lists 5 institution(s) in 1 country
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 41450326)
Free to read	2 / 2	Free to read
Total	47 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Related studies in Risk genes beyond APOE

Also in Risk genes beyond APOE

98 studies in the library are filed under Risk genes beyond APOE with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk genes beyond APOE hub.

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →